?

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition

Date: June 1, 2015
Pages: 54
Price:
US$ 800.00
Publisher: Koncept Analytics
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GAB9712C092EN
Leaflet:

Download PDF Leaflet

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition
Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA).

Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders. When oral supplements fail to meet the requirement, intravenous (I.V.) iron therapy is used, in which iron is directly injected with a needle into a vein. Iron given intravenously allows larger amounts of iron to be provided to patients while avoiding many of the side effects and treatment compliance issues associated with oral iron, and can result in faster rises in hemoglobin levels. In the US, a small fraction of non-dialysis CKD patients who are diagnosed with IDA are currently being treated with I.V. iron, and thus a significant opportunity is there for the market.

The key factors driving growth of the global I.V. iron industry include iron deficiency in hemodialysis patient cases, growing number of ERSD patients, prevalence of iron deficiency in women, increasing global healthcare expenditure, increasing global ageing population and large potential in new therapeutic areas. Some of the noteworthy trends and developments of this industry are penetration of I.V. iron in obstetrics and gynecology area, new product development and increase in awareness of disease. However, the growth of this sector is hindered by potential risks of using I.V. iron, emerging anemia management therapies and strict regulatory structures.

The report provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The competition in the global I.V. iron market is stiff among large players like Galenica Group, AMAG Pharmaceuticals Inc. and Actavis Plc. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
1. OVERVIEW

1.1 I.V. Iron Application Areas
  1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
  1.2.2 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment

2. MARKET ANALYSIS

2.1 Global Iron Product Market
-Market Value
-Market Segments
  2.2.1 Global I.V. Iron Drug Market
-Market Value
-Product Share
2.2 Regional Analysis
  2.2.1 The US I.V. Iron Drug Market
-Market Value
-Product Share
-Non-Dialysis IV Iron Market
  2.2.2 European I.V. Iron Drug Market
-Market Value
-Product Share
  2.2.3 Australian I.V. iron Drug Market
-Market Value
-Product Share

3. MARKET DYNAMICS

3.1 Growth Drivers
  3.1.1 Iron Deficiency in Hemodialysis Patients Cases
  3.1.2 Growing Number of ERSD Patients
  3.1.3 Prevalence of Iron Deficiency in Women
  3.1.4 Increasing Global Healthcare Expenditure
  3.1.5 Increasing Global Ageing Population
  3.1.6 Large Potential in New Therapeutic Areas
3.2 Key Trends
  3.2.1 I.V. Iron Penetration in Obstetrics and Gynecology Area
  3.2.2 New Product Development
  3.2.3 Increase Disease Awareness
3.3 Challenges
  3.3.1 Potential Risks of I.V. Iron
  3.3.2 Emerging Anemia Management Therapies
  3.3.3 Strict Regulatory Structures

4. COMPETITIVE LANDSCAPE

4.1 Global Market
4.2 Regional Market
  4.2.1 The US
  4.2.2 Europe
4.3 Product Comparison

5. COMPANY PROFILES

5.1 Galenica group
  5.1.1 Business Overview
  5.1.2 Financial Overview
  5.1.3 Business Strategies
-Executing an Iron Deficiency Franchise
-Exploit the Commercial Potential
5.2 AMAG Pharmaceuticals
  5.2.1 Business Overview
  5.2.2 Financial Overview
  5.2.3 Business Strategies
-Capture a Larger Market Share
-Feraheme in Non-Dialysis Adult CKD Patients
5.3 Actavis Plc
  5.3.1 Business Overview
  5.3.2 Financial Overview
  5.3.3 Business Strategies
-Development through Mergers & Acquisitions
-Differentiated and High-Demand Products

6. MARKET OUTLOOK

6.1 Market Forecast
6.2 Forecast Methodology
  6.2.1 Dependent and Independent Variables
  6.2.2 Correlation Analysis
  6.2.3 Regression Analysis

LIST OF CHARTS

Global Market for Iron Products (2010-2014)
Global Iron Products Market Share by Segments (2014)
Global I.V. Iron Drugs Market Value (2009-2014)
Global I.V. Iron Drug Market Sales by Product (2009-2014)
Global I.V. Iron Drug Market Share by Product (2014)
Global I.V. Iron Drug Market Share by Therapeutic Area (2014)
Global Breakdown of Treatments for Iron Deficiency (2014E)
US I.V. Iron Drug Market Value (2009-2014)
US I.V. Iron Drug Market Sales by Product (2009-2014)
US I.V. Iron Drug Market Share by Product (2014)
US Non-dialysis I.V. Iron Drug Market Volume (2010-2014)
US Non-dialysis I.V. Iron Drug Market Share by Product (2014)
European I.V. Iron Drug Market Value (2009-2014)
European I.V. Iron Drug Market Sales by Product (2009-2014)
European I.V. Iron Drug Market Share by Product (2014)
Australian I.V. Iron Drug Market Value (2009-2014)
Australian I.V. Iron Drug Market Share by Product (2014)
Global Dialysis Patients (2009-2014E)
Global Dialysis Patients by Type (2013)
Global Dialysis Patients by Region (2013)
Global ERSD Patients (2009-2014E)
Prevalence of Iron Deficiency in Women in US
US Female Population (2009-2014E)
Global Health Care Expenditure Per Capita (2009-2014E)
US Healthcare Expenditure Per Capita (2009-2014E)
Global Ageing Population Over 65 (2009-2014E)
Anemic Patients with Disease Type (2014E)
I.V. Iron Penetration Rate in Different Therapeutic Areas (2014)
Global I.V. Iron Drug Market Share by Company (2014)
I.V. Iron Drug Product Pricing (2014)
US I.V. Iron Drug Market Share by Company (2014)
US Non-dialysis I.V. Iron Drug Market Share by Company (2014)
European I.V. Iron Drug Market Share by Company (2014)
Galenica’s Revenue Share by Business Segments (2014)
Galenica’s Net Sales and Net Profit (2010-2014)
AMAG Pharmaceuticals’ Revenue and Net Income (2010-2014)
Actavis Plc.’s Revenue Share by Business Segments (2014)
Actavis Plc.’s Net Sales and Net Income (2010-2014)
Global I.V. Iron Drug Market Forecast (2014-2019F)

LIST OF TABLES

Risk Factors for CKD
Emerging Non-Intravenous Therapies for Anemia Management
I.V. Iron Product Comparison
Dependent & Independent Variables (2010-2014)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Skip to top


Ask Your Question

Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: